Awakn Partners With University Of Nottingham For Preclinical Testing Of Psychoactive Therapy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 15 2024
0mins
Source: Benzinga
Partnership Announcement: Awakn Life Sciences Corp. has partnered with the University of Nottingham to conduct in vivo testing of its aminoindane compound, focusing on its potential to improve social cognition and behaviors related to trauma-related mental health disorders like PTSD.
Research Progress: The study, led by Dr. Madeleine King, will use rodent models to assess the compound's efficacy, with results expected by the end of 2024, following a recent collaboration with Eurofins Discovery for in vitro pharmacology testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
